BioSpace News Archive

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that Company management will present at three investor conferences in September.

AVITA Medical, Inc. announced that COSMOTEC, an M3 Group Company, received insurance coverage in Japan for the RECELL® System for the treatment of acute burns.

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside chat at the Wells Fargo Healthcare Conference on Thursday, September 8that 10:25 AM ET.

Leukemia, a blood cancer, is the most common cancer diagnosed in children and adolescents and the second leading cause of all cancer deaths.

Aadi Bioscience, Inc. (NASDAQ: AADI), today announced that the Company will be participating in and hosting one-on-one meetings at the following conferences during September.

Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2022 fiscal year end financial results after the close of the U.S. financial markets on September 8, 2022.

Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of MPS I.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.

i-Cordis, LLC, an early-stage pharmaceutical company, has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for Heart Failure with preserved Ejection Fraction (HFpEF).